In this quarter's report, we cover catalysts from 17 drugs and have included a list of Large Impact catalysts in the drug, device/diagnostic, and natural resource areas through April 2015 from our sister product, CatalystTracker. In addition, each drug’s likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided.

Our Q4 2014 Outlook Report highlighted several high- impact catalysts that resulted in large stock price changes. The results of all of our Q4 catalysts can be found on Page 4 of this report. BioMedTracker Likelihood of Approval (LOA) opinions successfully predicted 67% of catalyst outcomes in Q4 2014.

For the full report, please download the PDF version at the top of this page.

For our disclosures, please read the BioMedTracker Research Standards.